MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)

Donavan T. Cheng, Talia Mitchell, Ahmet Zehir et al. · Journal of Molecular Diagnostics · 2015 · 2.2K citations · Full text

Medicine, Molecular Biology, Oncology +14

<i>MET</i> Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent <i>MET</i> Genomic Amplification and c-Met Overexpression

Mark M. Awad, Geoffrey R. Oxnard, David M. Jackman et al. · Journal of Clinical Oncology · 2016 · 688 citations · Full text

Medicine, Genetics, Oncology +17

Institutional implementation of clinical tumor profiling on an unselected cancer population

Lynette M. Sholl, T. Khanh, Priyanka Shivdasani et al. · JCI Insight · 2016 · 448 citations · Full text

Medicine, Pathology, Cancer Genetics +16

<i>MET</i> Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor Prognosis

Joanna H. Tong, Sai F. Yeung, Anthony W.H. Chan et al. · Clinical Cancer Research · 2016 · 447 citations · Full text

Medicine, Genetics, Oncology +13

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience

Lynette M. Sholl, Dara L. Aisner, Marileila Varella‐Garcia et al. · Journal of Thoracic Oncology · 2015 · 430 citations · Full text

Medicine, Genetics, Oncology +16